Navigation Links
Resverlogix Updates Shareholders on Accelerated Clinical Trial Plan
Date:10/16/2009

se and other vascular disorders. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our vision to be a leader in the research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. Addit
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
2. Resverlogix is Presenting at IAS HDL Workshop
3. Resverlogix Honoured with World Economic Forum Technology Pioneer Award
4. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
5. Resverlogix Share Option Extension
6. Resverlogix Notice of Conference Call & Webcast
7. /C O R R E C T I O N from Source -- Resverlogix Corp./
8. Industry Leaders Select Resverlogixs RVX-208
9. Resverlogixs Lead Drug Featured in Key Scientific Publication
10. Jan Gray Joins Resverlogix Board of Directors
11. Resverlogix Notice of Conference Call & Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 Deep Research Report on ... research report on the transformer market. The report ... and industry chain structure as well as industry ... including China’s domestic market as well as global ... analysis. The report also covers information on policy, ...
(Date:11/21/2014)... SAN DIEGO , Nov. 20, 2014  Cytori ... CEO Marc Hedrick , M.D. will present live at ... December 4, 2014 TIME:    11:15 am PT / ... paste this URL into your browser,s address bar: http://bit.ly/1B2KGaL ... save time and receive event updates. This ...
(Date:11/18/2014)... 17, 2014 RPS Diagnostics (RPS®) ... – today announces its third annual partnership of ... Get Smart About Antibiotics Week from November 17-23. ... national campaign designed to highlight the coordinated efforts ... non-profit and for-profit partners to provide education about ...
(Date:11/18/2014)... San Diego, CA (PRWEB) November 17, 2014 ... Emerson of Salk , Dr. Beverly Emerson, a professor in ... behavior of genes. Her most recent discovery points to an ... about Dr. Emerson’s career and how her local research is ... Emerson will present her findings and then join host Cheryl ...
Breaking Biology Technology:International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 2International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3
... International Corporation (NASDAQ: PRXL ) announced today that ... in New York.  Josef von Rickenbach, Chairman and Chief Executive ... p.m.  ET on Wednesday, September 7, 2011.   ... Growth Stock Conference in New York.  Josef von Rickenbach, Chairman ...
... Savvier consumers and competition from generic drugs have made ... maturity, more elusive.  At the same time, new technologies ... to support pharmaceutical brand growth. While biopharma ... brands, recent field research from Best Practices, LLC suggests ...
... manufacturer of advanced cell imaging systems, today announced that the ... division of Merck KGaA of Germany.  The transaction is subject ... in the fourth quarter of 2011. The terms of the ... of USD 14 million (EUR 10 million) in 2010 and ...
Cached Biology Technology:PAREXEL International to Present at Robert Baird Healthcare Conference and William Blair Emerging Growth Stock Conference 2Using Public Relations to Launch, Grow, and Extend Pharmaceutical and Biotech Brands 2Amnis Acquired by EMD Millipore - Expands Growth Potential 2Amnis Acquired by EMD Millipore - Expands Growth Potential 3
(Date:11/15/2014)... , Nov. 13, 2014  While we may still be ... McCoy used in "Star Trek" to gain instant access to ... to work with smartphones and tablets for monitoring and measuring ... healthcare world. This may seem a tad Orwellian to some, ... adopt some of these technological opportunities into their healthcare regime. ...
(Date:11/7/2014)... conjunction with the Glendale and ... the Verdugos has announced the " GLENDALE - ... to keep the Verdugo Regional Crime Lab operational after its ... existence, the Lab has processed more than 400 DNA samples, ... "Because our number one priority is the wellbeing of ...
(Date:11/6/2014)... November 6, 2014 - Insilico Medicine, Inc, a ... and age related diseases announced a research collaboration ... cancer, Champions Oncology, Inc (OTC: CSBR). , "There ... personalized medicine, but Champions Oncology,s TumorGraft technology is ... the chemotherapy regimen experimentally generating vast amounts of ...
Breaking Biology News(10 mins):Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... evolve to survive climate change may depend on the ... mathematical model that simulates the effect of climate change ... early online edition of Evolutionary Applications , are ... change in the past might not be able to ...
... discovered that an active ingredient in the Persian spice saffron ... as multiple sclerosis. Chris Power and a team ... published their findings in the peer-reviewed publication, The Journal ... compound in saffron, known as crocin, that exerts a protective ...
... A new chemical process developed by a team ... Emission Tomography (PET) in creating real-time 3-D images of ... new work by Tobias Ritter, Associate Professor of Chemistry ... possibility of using PET scans to peer into any ...
Cached Biology News:Biodiversity can promote survival on a warming planet 2Medical researchers make important research link between active ingredient in saffron and MS 2Tracing biological pathways 2
Component of HyperMu™ Insertion Kit...
...
Request Info...
... Rabbits x 2 , ... bleed x1 /each , Immunizations/Boost injections ... (app. 5 ml) x1 /each , ... /each , Final Bleed ~ 100 ml blood ...
Biology Products: